Levosimendan Prevents Pressure-Overload-induced Right Ventricular Failure

Area of Science:

• Cardiology
• Pharmacology
• Animal Models

Background:

• Investigated chronic levosimendan's efficacy in preventing and reverting pressure-overload-induced right ventricular hypertrophy and failure.
• Utilized a rat model with pulmonary trunk banding (PTB) to induce right ventricular pressure overload.

Purpose of the Study:

• To determine if levosimendan can prevent the onset of right ventricular failure.
• To assess levosimendan's ability to reverse established right ventricular dysfunction and improve contractility.

Main Methods:

• Wistar rats underwent pulmonary trunk banding (PTB) to induce right ventricular hypertrophy and failure.
• Levosimendan treatment administered preventatively (3 days pre-surgery) or as reversal therapy (3 weeks post-surgery).
• Right ventricular function assessed via echocardiography, MRI, pressure-volume loops, and histology 7 weeks post-surgery.

Main Results:

• Levosimendan prevented the decline in cardiac index (CI) and right ventricular ejection fraction (RVEF) in the prevention group.
• Treated rats showed preserved CI and RVEF, comparable to sham-operated controls.
• Levosimendan improved right ventricular contractility in the reversal group, as indicated by increased preload recruitable stroke work.

Conclusions:

• Chronic levosimendan treatment is effective in preventing the development of right ventricular failure.
• Levosimendan demonstrates a significant ability to improve contractility in established cases of pressure-overload-induced right ventricular failure.